Utility of F-18 fluorodeoxyglucose positron emission tomography/computed in carcinoma of unknown primary

Basit Öğe Kaydı
dc.authorid0000-0002-6245-9349
dc.authorid0000-0001-5364-1299
dc.authorid0000-0002-3650-8258
dc.authorscopusid6601968201
dc.authorscopusid35949526800
dc.authorscopusid56490954700
dc.authorscopusid57214923299
dc.authorscopusid56356834500
dc.authorwosidAktolun, Cumali/K-8514-2018
dc.authorwosidÇelen, Yusuf Zeki/AAG-8083-2020
dc.authorwosidSahin, Ertan/AAG-8999-2020
dc.authorwosidELBOGA, UMUT/AAH-1320-2020
dc.contributor.authorElboğa, Umut
dc.contributor.authorKervancioglu, Selim
dc.contributor.authorŞahin, Ertan
dc.contributor.authorBaşıbüyük, Mustafa
dc.contributor.authorÇelen, Y. Zeki
dc.contributor.authorAktolun, Cumali
dc.date.accessioned2022-05-11T14:40:53Z
dc.date.available2022-05-11T14:40:53Z
dc.date.issued2014
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Nükleer Tıp Ana Bilim Dalı
dc.description.abstractCarcinoma of unknown primary (CUP) is a heterogeneous group of tumors with various clinical features causing diagnostic and therapeutic challenges. The aim of this study was to evaluate the ability of F-18 FDG PET/CT for localizing the primary tumor, disclosing additional metastases, and changing the treatment in patients with CUP. One hundred and twelve metastatic patients (female = 40, male = 72, median age = 60.5 years) in whom conventional diagnostic work-up failed to disclose the primary tumor were included in the study. F-18 FDG PET/CT imaging was performed in a standard protocol (patient supine, arms on patient's side, vertex to thigh, 369.3 MBq (296-444 MBq) F-18 FDG, a 60-minute uptake period, 6-7 bed position). Histopathology was taken as the only reference standard. F-18 FDG PET/CT correctly detected primary tumor in 37 of 112 (33.03%) patients. The most common site of primary tumor detected by F-18 FDG PET/CT was lung (n = 18), which was followed by nasopharynx (n = 7), pancreas (n = 5), tonsil (n = 2), breast (n = 2), thyroid (n = 1), uterus (n = 1) and colon/rectum (n = 1). F-18 FDG PET/CT imaging disclosed additional previously undetected metastases in 32 (28.5%) and changed the treatment in 33 (29.4%) of 112 patients. There were false positive F-18 FDG PET/CT results in 21 (18.5%) patients. F-18 FDG PET/CT is able to disclose the primary tumor, disclose new metatases and change the treatment in about one third of patients with CUP.
dc.identifier.endpage8946
dc.identifier.issn1936-2625
dc.identifier.issue12en_US
dc.identifier.pmid25674269
dc.identifier.scopus2-s2.0-84921454221
dc.identifier.scopusqualityN/A
dc.identifier.startpage8941
dc.identifier.urihttps://hdl.handle.net/20.500.11776/8947
dc.identifier.volume7
dc.identifier.wosWOS:000348345900073
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorŞahin, Ertan
dc.language.isoen
dc.publisherE-Century Publishing Corp
dc.relation.ispartofInternational Journal of Clinical and Experimental Pathology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectCarcinoma of unknown primary
dc.subjectF-18 FDG PET/CT
dc.subjectmetastases
dc.subjecttreatment change
dc.subjectPrimary Tumors
dc.subjectFdg-Pet
dc.subjectPrimary Site
dc.subjectTherapeutic Management
dc.subjectCancer
dc.subjectMetastases
dc.subjectDiagnosis
dc.subjectOrigin
dc.subjectCup
dc.titleUtility of F-18 fluorodeoxyglucose positron emission tomography/computed in carcinoma of unknown primary
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
8947.pdf
Boyut:
1.45 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu